mTOR inhibitors showing promise in lab studies targeting MYCN

###New treatment approach may offer hope to patients with aggressive childhood cancers

Scientists at The Institute of Cancer Research, London, identified that compounds which attack a cell signaling pathway linked to cancer metabolism called mTOR are highly effective both against neuroblastoma cells grown in dishes and in mice with MYCN-driven cancers.

“Our study highlights that one particular class of drug, very potent allosteric mTOR kinase inhibitors, show particular promise for pediatric patients when MYCN is expressed. And understanding how the drug works — by blocking both mTORC1 and mTORC2 — reveals a crucial vulnerability in neuroblastoma tumours which we hope we can exploit in the clinic.”

1 Like